Pulse Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74587B1017
USD
13.27
0.28 (2.16%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Pulse Biosciences, Inc. stock-summary
stock-summary
Pulse Biosciences, Inc.
Pharmaceuticals & Biotechnology
Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
Company Coordinates stock-summary
Company Details
3957 Point Eden Way , HAYWARD CA : 94545-3720
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 21 Schemes (4.46%)

Foreign Institutions

Held by 29 Foreign Institutions (0.45%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Robert Duggan
Independent Chairman of the Board
Mr. Darrin Uecker
President, Chief Executive Officer, Director
Mr. Kenneth Clark
Independent Director
Mr. Mitchell Levinson
Independent Director
Mr. Manmeet Soni
Independent Director
Dr. Mahkam Zanganeh
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-19 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,012 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

-63.29%

stock-summary
Price to Book

9.68